CAS: 1613191-99-3; 2-Amino-6-Fluoro-N-(5-Fluoro-4-(4-(4-(Oxetan-3-yl)Piperazine-1-Carbonyl)Piperidin-1-yl)Pyridin-3-yl)Pyrazolo[1,5-A]Pyrimidine-3-Carboxamide
该化合物是针对DNA损害反应(DDD)路径的关键调节者ATR(ATATSIA Telangiectasia和Rad3相关)动脉酶的选择性抑制剂. Gartisertib通过阻止ATR, 干扰DNA复制压力的修复, 特别是在有缺陷的解甲还乡机制的癌症细胞中, 如那些存在ATM突变或其他基因不稳定的细胞中. 这种复合物在临床前模式中显示出强大的抗图象活动, 显示出与基于白金的乳房疗养剂或PARP抑制剂等DNA破坏剂的协同效应. 它的高选择性和有利的药用生植物特征降低了目标外效应, 增强了治疗潜力. Gartisertib正在调查固体肿瘤的治疗, 提供了一种很有希望的策略, 用于解甲返金恶性肿瘤的精确度.
- 英文名称2-Amino-6-Fluoro-N-(5-Fluoro-4-(4-(4-(Oxetan-3-yl)Piperazine-1-Carbonyl)Piperidin-1-yl)Pyridin-3-yl)Pyrazolo[1,5-A]Pyrimidine-3-Carboxamide
- 中文名称2-氨基-6-氟-N-(5-氟-4-(4-(4-(噁丁环烷-3-基)哌嗪-1-羰基)哌啶-1-基)吡啶-3-基)吡唑并[1,5-A]嘧啶-3-甲酰胺
- IUPAC名称2-amino-6-fluoro-N-(5-fluoro-4-(4-(4-(oxetan-3-yl)piperazine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
- 其它别名Gartisertib; 2-Amino-6-Fluoro-N-(5-Fluoro-4-(4-(4-(Oxetan-3-yl)Piperazine-1-Carbonyl)Piperidin-1-yl)Pyridin-3-yl)Pyrazolo[1,5-A]Pyrimidine-3-Carboxamide; Gartisertib [inn]; 7Om98Iud1O; 2-Am
- CAS编号1613191-99-3
- MFCD编号:MFCD31803930
- FDA UNII编号:7OM98IUD1O
- 分子式:C25H29F2N9O3分子量:541.56
- 产品CID: 814116
- 产品分类有机原料 → 有机杂环化合物 → 吡唑并嘧啶类
物理性质
MSDS等安全信息
上下游产品
1-(3-(2-Amino-6-Fluoropyrazolo[1,5-A]Pyrimidine-3-Carboxamido)-5-Fluoropyridin-4-yl)Piperidine-4-Carboxylic Acid 1613192-02-1Tert-Butyl 1-[3-[(2-Amino-6-Fluoro-Pyrazolo[1,5-A]Pyrimidine-3-Carbonyl)Amino]-5-Fluoro-4-Pyridyl]Piperidine-4-Carboxyiate 1613192-00-9
(6-Chlorobenzotriazol-1-yl)-2-Amino-6-Fluoropyrazolo[1,5-A]Pyrimidine-3-Carboxylate 1613191-78-8
Allyl 2-Amino-6-Fluoro-Pyrazolo[1,5-A]Pyrimidine-3-Carboxylate 1613191-76-6
2-Amino-6-Fluoropyrazolo[1,5-A]Pyrimidine-3-Carboxylic Acid 1613191-77-7
合成工艺路线路线简述
- 合成目标产物 2-Amino-6-Fluoro-N-(5-Fluoro-4-(4-(4-(Oxetan-3-yl)Piperazine-1-Carbonyl)Piperidin-1-yl)Pyridin-3-yl)Pyrazolo[1,5-A]Pyrimidine-3-Carboxamide(Wxc04788) 主要起始原料 1-(Oxetan-3-yl)Piperazine And 4-Piperidinecarboxylic Acid, 1-[3-[[(2-Amino-6-Fluoropyrazolo[1,5-A]Pyrimidin-3-yl)Carbonyl]Amino]-5-Fluoro-4-Pyridinyl]-, Hydrochloride (1:1)
- (文献来源)合成步骤主要原料 1-(Oxetan-3-yl)Piperazine 和 4-Piperidinecarboxylic Acid, 1-[3-[[(2-Amino-6-Fluoropyrazolo[1,5-A]Pyrimidin-3-yl)Carbonyl]Amino]-5-Fluoro-4-Pyridinyl]-, Hydrochloride (1:1)
📜5-溴-3-氟吡啶置于吡啶,二苯甲酮亚胺,Tris-(Dibenzylideneacetone)Dipalladium(0),正丁基锂,N-[(6-Chlorobenzotriazol-1-yl)Oxy-(Dimethylamino)Methylene]-Dimethyl-Ammonium Tetrafluoroborate,Sodium Carbonate,Caesium Carbonate,N,N-二异丙基乙胺,4,5-双二苯基膦-9,9-二甲基氧杂蒽体系中,用 四氢呋喃,1,4-二氧六环,正己烷,乙腈,环己醇 用作溶剂,化学反应 18.5H,反应生成2-氨基-6-氟-N-(5-氟-4-(4-(4-(噁丁环烷-3-基)哌嗪-1-羰基)哌啶-1-基)吡啶-3-基)吡唑并[1,5-A]嘧啶-3-甲酰胺
参考文献:Compounds Useful As Inhibitors Of Atr Kinase
标题:Compounds Useful As Inhibitors Of Atr Kinase
摘要:本发明涉及作为atr蛋白激酶抑制剂的化合物.该发明涉及包括本发明化合物的药学上可接受的组合物;使用本发明化合物治疗各种疾病,疾病和症状的方法;制备本发明化合物的方法;制备本发明化合物的中间体;以及本发明化合物的固体形式. 本发明的化合物具有式i-A或i-B: 其中变量如本文所定义.
海关参考信息
- 2905121000-正丙醇
2912110000-甲醛
2912120000-乙醛
2921211000-乙二胺 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Jo U, Senatorov IS, Zimmermann A, Saha LK, Murai Y, Kim SH, Rajapakse VN, Elloumi F, Takahashi N, Schultz CW, Thomas A, Zenke FT, Pommier Y. Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents. Mol Cancer Ther. 2021 Aug;20(8):1431-1441. doi: 10.1158/1535-7163.MCT-20-1026. Epub 2021 May 27. 118(6):e2015654118. doi: 10.1073/pnas.2015654118.
3: Gorecki L, Andrs M, Rezacova M, Korabecny J. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy. Pharmacol Ther. 2020 Jun;210:107518. doi: 10.1016/j.pharmthera.2020.107518. Epub 2020 Feb 26.
207:107450. doi: 10.1016/j.pharmthera.2019.107450. Epub 2019 Dec 11. 39(20):5940-52. doi: 10.1021/bi9929498.
📝 需求与反馈
尽可能描述清楚需求与问题信息
